Dr. Chase Spurlock, Founder and CEO of IQuity

PAN9: IQuity with Dr. Chase Spurlock

Posted on Posted in Podcast

“In the field of immunology, the big, bad wolf is autoimmune disease,” said Dr. Chase Spurlock, Founder and CEO of IQuity. IQuity is working to provide physicians tools to make early diagnosis possible in difficult neurological conditions like MS. The ability to diagnosis autoimmune disease early can have a positive impact on both patient outcomes and society as a whole. For example, did you know that MS is the leading non-traumatic cause of disability in young adults?

IQuity just launched a RNA signature blood test that can help physicians determine early on whether a person has MS. This is ground breaking research that has the ability to dramatically shorten the period of time that a person has to wait for diagnosis. Now this does not replace traditional measures like lumbar puncture or MRI studies, rather it is a tool that physicians can use if they believe a person is showing clinical indicators for MS.

In this podcast, we speak with Dr. Spurlock about this breakthrough research and the other work being done at IQuity in Nashville, TN. Whether you are a patient or a physician, you’ll want to tune in to learn more about this scientific breakthrough.

About Dr. Chase Spurlock

Dr. Spurlock is committed to translating basic science discoveries into improved diagnostic strategies for patients with autoimmune conditions. As CEO of IQuity, he has day-to-day oversight of all aspects of the company ensuring the vision and mission is realized.

Dr. Spurlock’s published work explores the molecular basis for autoimmune disease and further examines therapeutic targets in the management of these diseases leveraging a diverse set of genomic and biochemical approaches including gene expression and next-generation sequencing technologies.

Dr. Spurlock is a Phi Beta Kappa graduate of The University of the South where he received his bachelor’s degree in biology, magna cum laude, with departmental honors. He earned his Ph.D. in microbiology and immunology from Vanderbilt University School of Medicine where he was awarded the Sidney P. Colowick award for outstanding research.

About IQuity

IQuity is a life science technology company leveraging machine learning methods to deliver breakthrough RNA diagnostics and analytics. The company’s initial offerings include Isolate tests across neurology, gastroenterology and rheumatology that are based on proprietary algorithms capable of ruling in or ruling out specific autoimmune diseases.

IQuityThe accuracy of these methods at the earliest onset of symptoms exceeds 90% and offers providers the ability to shorten the diagnostic process for autoimmune disease and related conditions. Most autoimmune diseases take months to years to diagnose. IQuity’s technology, IQIsolate, analyzes RNA expression data from a blood sample to identify presence or absence of disease at the cellular level and deliver a result to providers in only 7 days. RNA expression is representative of the presence of disease in real time, whereas changes in DNA indicate potential risk of disease.

Early diagnosis and treatment lead to optimal patient outcomes by reducing long-term, irreparable damage to the body and lowering lifetime healthcare costs. Located in Nashville, TN, IQuity is firmly committed to data transparency and scientific peer review and will perform its tests in its independent CLIA-certified lab.

Episode Outline

  • About Dr. Chase Spurlock
  • Immunology, RNA Signatures and Autoimmune Disease
  • Decoding the RNA Message as an Indicator for Autoimmune Disease
  • RNA Signature Blood Test Launched to help Diagnose and Treat Multiple Sclerosis
  • IQuity MS Blood Test as a MS Diagnostic Tool for Doctors
  • Benefits of Early Detection and Treatment
  • How the Data is Collected and Analyzed
  • Where the Samples are Evaluated
  • How to Contact iQuity
  • Closing Thoughts

Related Links

Thank you for tuning into this episode of the Patient Activation Network podcast. Please like and share this to spread the word. Stay tuned for the next episode.

Leave a Reply

Your email address will not be published. Required fields are marked *